MALVERN, Pa., July 22, 2013 /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) today announced that it has appointed Don DeGolyer as Chief Operating Officer, Pharmaceuticals, which includes Endo Pharmaceuticals and Qualitest, effective August 1, 2013.
"Don is a uniquely qualified, seasoned leader with nearly three decades of experience in the healthcare industry. Don has broad experience in both branded and generic pharmaceuticals and I have tremendous confidence in his ability to drive operational excellence and growth," said Rajiv De Silva, President and Chief Executive Officer of Endo Health Solutions.
"I am extremely excited to join Rajiv and the other members of the Endo team as the company enters a new phase of growth and expansion," said Don DeGolyer. "I believe that Endo is in an excellent position to deliver value to customers, employees and shareholders over the near term and I look forward to being a part of this exciting transformation."
Most recently, Mr. DeGolyer served as President and CEO of Sandoz Inc., Novartis' North America generic pharmaceuticals unit. Prior to joining Novartis in 2002, he spent 11 years at Johnson & Johnson in various roles of increasing responsibility, including Vice President of Marketing and Sales, and began his career at Pfizer, Inc.About EndoEndo Health Solutions Inc. (Endo) is a U.S.-based specialty healthcare company with four distinct business segments that are focused on branded and generic pharmaceuticals, devices and services, each providing quality products to our customers while improving the lives of patients. Through our operating companies – AMS, Endo Pharmaceuticals, HealthTronics and Qualitest – Endo is dedicated to finding solutions for the unmet needs of patients. Learn more at www.endo.com. Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV